- China Life Capital led the latest financing, according to Shangdao Venture Capital Network.
- The company plans to invest in AI models and high-throughput automated laboratories.
Funding for biological models
Beijing-based AI biotechnology company BioGeometry has raised more than $100 million across its Series A financing, Shangdao Venture Capital Network reported on October 28, citing information obtained from official sources. China Life Capital led the latest funding, with existing investor Shanghai Biomedical Fund increasing its investment.
The report named CDB Science and Technology Innovation, Ruili Investment and Guofang Capital among participating investors. Existing backer Fortune Capital also invested again, while Index Capital continued as exclusive financial adviser.
Models and laboratories
BioGeometry develops generative AI models spanning molecules and cells. Its GeoFlow system addresses molecular structures and design, while GeoCell models cellular responses to genetic or drug interventions, according to the report.
Founder and CEO Tang Jian said the funding would support further model development and expansion of high-throughput automated laboratories. The company also plans to advance its own drug candidates and synthetic biology products toward commercial use. These are intended uses of the capital; the report does not establish clinical success or quantify the latest individual round.
Sources & context
Go to the original material. Company claims remain attributed to their sources.
01
